Imran H Iftikhar1, Mathew Schimmel2, William Bender2, Colin Swenson2, David Amrol3. 1. Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA. imran.hasan.iftikhar@emory.edu. 2. Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA. 3. Division of Allergy and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Abstract
BACKGROUND: Several new biologics have been studied in patients with eosinophilic asthma with varying degrees of response on clinical outcomes. No head-to-head trial has directly compared the efficacy of these drugs. OBJECTIVE: To synthesize data on the relative efficacy of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab using network meta-analysis. DATA SOURCES: We searched PubMed from inception to December 15th, 2017. DATA EXTRACTION AND SYNTHESIS: We used the 'frequentist' methodology with random effect models using primarily 'netmeta' function in R to generate network meta-analysis results. Outcomes assessed included changes in forced expiratory volume-in 1 s (FEV1), asthma control questionnaire (ACQ), and asthma quality of life questionnaire (AQLQ). We also separately analyzed the annualized rate ratios for asthma exacerbations for each drug and compared to placebo. For all outcomes assessed, all drugs were superior to placebo except tralokinumab. In terms of magnitude of effect, dupilumab, followed by reslizumab and benralizumab showed the greatest increase in FEV1, 0.16L (95% CIs: 0.08-0.24), 0.13L (0.10-0.17), and 0.12L (0.08-0.17), compared to placebo. While mepolizumab, followed by dupliumab, benralizumab, and reslizumab showed reductions in ACQ scores, in order of magnitude of effect, dupilumab, followed by mepolizumab, benralizumab, and reslizumab showed the greatest increase in AQLQ scores. All drugs decreased asthma exacerbations but the results were only significant for reslizumab and dupilumab. CONCLUSIONS: All drugs except for tralokinumab showed improvements in FEV1, ACQ, and AQLQ. Only reslizumab and dupilumab were associated with statistically significant reductions in asthma exacerbation rates.
BACKGROUND: Several new biologics have been studied in patients with eosinophilic asthma with varying degrees of response on clinical outcomes. No head-to-head trial has directly compared the efficacy of these drugs. OBJECTIVE: To synthesize data on the relative efficacy of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab using network meta-analysis. DATA SOURCES: We searched PubMed from inception to December 15th, 2017. DATA EXTRACTION AND SYNTHESIS: We used the 'frequentist' methodology with random effect models using primarily 'netmeta' function in R to generate network meta-analysis results. Outcomes assessed included changes in forced expiratory volume-in 1 s (FEV1), asthma control questionnaire (ACQ), and asthma quality of life questionnaire (AQLQ). We also separately analyzed the annualized rate ratios for asthma exacerbations for each drug and compared to placebo. For all outcomes assessed, all drugs were superior to placebo except tralokinumab. In terms of magnitude of effect, dupilumab, followed by reslizumab and benralizumab showed the greatest increase in FEV1, 0.16L (95% CIs: 0.08-0.24), 0.13L (0.10-0.17), and 0.12L (0.08-0.17), compared to placebo. While mepolizumab, followed by dupliumab, benralizumab, and reslizumab showed reductions in ACQ scores, in order of magnitude of effect, dupilumab, followed by mepolizumab, benralizumab, and reslizumab showed the greatest increase in AQLQ scores. All drugs decreased asthma exacerbations but the results were only significant for reslizumab and dupilumab. CONCLUSIONS: All drugs except for tralokinumab showed improvements in FEV1, ACQ, and AQLQ. Only reslizumab and dupilumab were associated with statistically significant reductions in asthma exacerbation rates.
Authors: Eugene R Bleecker; J Mark FitzGerald; Pascal Chanez; Alberto Papi; Steven F Weinstein; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Magnus Aurivillius; Viktoria Werkström; Mitchell Goldman Journal: Lancet Date: 2016-09-05 Impact factor: 79.321
Authors: Gary T Ferguson; J Mark FitzGerald; Eugene R Bleecker; Michel Laviolette; David Bernstein; Craig LaForce; Lyndon Mansfield; Peter Barker; Yanping Wu; Maria Jison; Mitchell Goldman Journal: Lancet Respir Med Date: 2017-05-22 Impact factor: 30.700
Authors: Sally Wenzel; Mario Castro; Jonathan Corren; Jorge Maspero; Lin Wang; Bingzhi Zhang; Gianluca Pirozzi; E Rand Sutherland; Robert R Evans; Vijay N Joish; Laurent Eckert; Neil M H Graham; Neil Stahl; George D Yancopoulos; Mariana Louis-Tisserand; Ariel Teper Journal: Lancet Date: 2016-04-27 Impact factor: 79.321
Authors: Michael Noonan; Phillip Korenblat; Sofia Mosesova; Heleen Scheerens; Joseph R Arron; Yanan Zheng; Wendy S Putnam; Merdad V Parsey; Sean P Bohen; John G Matthews Journal: J Allergy Clin Immunol Date: 2013-05-29 Impact factor: 10.793
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen Journal: Thorax Date: 2015-05-22 Impact factor: 9.139
Authors: Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: Andras Bikov; Ipek Kivilcim Oğuzülgen; Ilaria Baiardini; Marco Contoli; Alexander Emelyanov; Omar Fassio; Juan Carlos Ivancevich; Igor Kaidashev; Krzysztof Kowal; Marina Labor; Lies Lahousse; Stefan Mihaicuta; Silviya Novakova; Alicia Padilla Galo; Alexander Simidchiev; Angelica Tiotiu; Ignacio J Ansotegui; Jonathan A Bernstein; Louis Philippe Boulet; Giorgio Walter Canonica; Lawrence Dubuske; Nelson Rosario; Pierachille Santus; Fulvio Braido Journal: World Allergy Organ J Date: 2020-07-31 Impact factor: 4.084
Authors: Mark B Jones; Carlos A Alvarez; Jenny L Johnson; Julie Y Zhou; Nathan Morris; Brian A Cobb Journal: PLoS One Date: 2019-05-23 Impact factor: 3.240